RIPK3 and renal cell carcinoma: In vivo and in vitro experiments confirmed that the combined therapy significantly outperformed sunitinib alone, which indicates that the clinical potential of combining TKI with Smac mimetics in SPOP/RIPK1/RIPK3 dysfunction tumors represented by RCC.